LTB 4 is a leukotriene involved in inflammation. It is produced from leukocytes in response to inflammatory mediators and is able to induce the adhesion and activation of leukocytes on the endothelium, allowing them to bind to and cross it into the tissue. [1] .

Leukotriene B4 (LTB4) is a major type of lipid mediator that is rapidly generated from arachidonic acid through sequential action of 5-lipoxygenase (5-LO), 5-lipoxygenase-activating protein (FLAP) and LTA4 hydrolase (LTA4H) in response to various stimuli.

Leukotriene B4 is a leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway. It has a role as a human metabolite, a mouse metabolite, a plant metabolite and a vasoconstrictor agent.

Leukotriene B 4 (LTB4) is a proinflammatory lipid mediator generated from arachidonic acid through the sequential activities of 5–lipoxygenase, 5–lipoxygenase–activating protein, and leukotriene A 4 hydrolase 16.

LTB4 is a potent chemoattractant, facilitating leukocyte adhesion and recruitment and its role in the pathogenesis of atherosclerosis is well established. LTA4 can be conjugated with glutathione through the enzyme LTC4 synthase to produce Leukotriene C4 (LTC4).

Leukotriene B 4 (LTB 4) is an endogenous lipid mediator of inflammation derived from arachidonic acid by the sequential action of cytosolic phospholipase A 2 and 5-lipoxygenase. This mediator was initially recognized for its involvement in the recruitment of neutrophils.

Leukotriene B 4 (LTB 4), a lipid mediator produced from arachidonic acid, is a chemoattractant for inflammatory leukocytes. We identified two receptors for LTB 4, the high-affinity receptor BLT1 and the low-affinity receptor BLT2.